Preclinical safety of recombinant human interleukin-18

Toxicologic Pathology

Volumn 31, Issue 5, 2003, Pages 554-561

  Herzyk, Danuta J ^a   Bugelski, Peter J ^a,b   Hart, Timothy K ^a   Wier, Patrick J ^a  

^a GLAXOSMITHKLINE   (United States)

^b CENTOCOR INC   (United States)

Author keywords

IL 18; Mice; Monkeys; Nephrotoxicity

Indexed keywords

IBOCTADEKIN; RECOMBINANT INTERLEUKIN 18; TAMM HORSFALL GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ELECTRON MICROSCOPY; FEMALE; HEMATOCRIT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHOID HYPERPLASIA; MALE; MONKEY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THROMBOCYTE COUNT;

ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-18; KIDNEY; LYMPH NODES; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MUCOPROTEINS; NEPHROSIS, LIPOID; RECOMBINANT PROTEINS; SPLEEN; TIME FACTORS;

ANIMALIA; MACACA FASCICULARIS; MURINAE;

EID: 0141563862     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230309794     Document Type: Article

References (33)

1. Ault BH, Stapleton FB, Gaber L, et al (1988). Acute renal failure during therapy with recombinant human gamma interferon. N Eng J Med 319: 1397-1400.
2. Averbuch SD, Austen HA III, Sherwin SA, et al (1984). Acute interstitial nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Eng J Med 310: 32-35.
3. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ (1994). Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 204: 1150-1157.
4. Bugelski PJ, Solleveld HA, Fong K-LL, et al (1992). Myeloma-like cast nephropathy caused by human recombinant soluble CD4 (sCD4) in monkeys. Amer J Pathol 140: 531-537.
5. Carr BD, Eng VM, Lipman JM, Anderson TD (1999). The toxicology of interleukin-12: A review. Toxicol Path 27: 58-63.
6. Castel JV, Gomez-Lechon MJ, David M, et al (1988). Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347-350.
7. Clyne DH, Pesce AJ, Thompson RE (1979). Nephrotoxicity of Bence Jones proteins in the rat: Importance of preotein isoelectric point. Kidney Int 16: 345-352.
8. Dinarello CA (1999). IL-18: A Th1-inducing proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103: 11-24.
9. Evans RD, Argiles JM, Williamson DH (1989). Metabolic effects of tumour necrosis factor-α (chachectin) and interleukin-1. Clin Sci 77: 357-364.
10. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB (2000). Phase I trial of twice-weekly intravenous interleukin12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6: 1678-1692.
11. Gossett KA, Barbolt TA, Cornacoff JB, et al (1993). Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys. Toxicol Pathol 21: 46-53.
12. Hamburger J (1979). Glomerulonephritis-pathogenesis. In: Nephrology, Hamburger J, Crosnier J, Grunfield J-P (eds). John Wiley and Sons, New York, pp 543-552.
13. Herzyk DJ, Soos JM, Maier CC, et al (2002). Immunopharmacology of recombinant human interleukin-18 in non-human primates. Cytokine 20: 38-48.
14. Jonak ZL, Trulli S, Maier CC, et al (2002). High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J Immunother 25 (Suppl 1): S20-S27.
15. Komada Y, Zhou YW, Zhang XL (1997). Fas/APO-1 (CD-95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Brit J Haematol 96: 147-157.
16. Koss MN, Pirani CL, Osserman EF (1976). Experimental Bence Jones cast nephropathy. Lab Invest 34: 579-591.
17. Lauw FN, Dekkers PEP, teVelde AA, et al (1999). Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. J Inf Dis 179: 646-452.
18. Lotze MT (1997). Future directions for recombinant interleukin-2 in cancer: A chronic inflammatory disorder. Cancer J from Scientific American 3 (Supp 1): S106-S108.
19. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F. Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M (1996). Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26: 1647-1651.
20. Mosmann TR, Sad S (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146.
21. Okamura H, Nagata K, Komatsu T, et al (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91.
22. Okamura H, Tsutsi H, Komatsu M, et al (1998). Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 10: 259-264.
23. Osaki T, Péron J-M, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H (1998). Interferon-gamma-inducing factor/Interleukin 18 administration mediates interleukin 12 and interferon-gamma independent anti-tumor effects. J Immunol 160: 1742-1749.
24. Parmiani G, Rivoltini L, Andreola G, Carraba M (2000). Cytokines in cancer therapy. Immunol Lett 74: 41-44.
25. Reddy P, Teshima T, Kukuruga M, et al (2001). Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 194: 1433-1440.
26. Robinson D, Shibuya K, Mui A, et al (1997). IGFI does not drive Th1 development but synergizes with IL-12 for interferonγ production and activates IRAK and NK-κB. Immunity 7: 571-581.
27. Sarmiento UM, Riley JH, Knaack PA, et al (1994). Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71: 862-873.
28. Seran G, Percheck M, Figlin R, Ardalan B (1986). Phase I study of recombinant β ser 17 interferon in the treatment of cancer. Cancer Treat Report 70: 1365-1372.
29. Terrell TG, Green JD (1993). Comparative pathology of recombinant murine interferon-γ in mice and recombinant human interferon-γ in cynomolgus monkeys. Int Rev Exp Pathol 34B: 73-101.
30. Trinchieri G (1994). Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027.
31. Verroust P, Morel-Maroger L, Preud'homme JL (1982). Renal lesions in dysproteinemias. Springer Semin Immunopathol 5: 333-356.
32. Vial T, Descotes J (1994). Clinical toxicity of the interferons. Drug Safety 10: 115.
33. Zwicle CM, Hughes BL, Piroozi KS, et al (1996). Immunogenicity of tissue plasminogen activators in rhesus monkeys: Antibody formation and effects on blood level and enzymatic activity. Fund Appl Toxicol 30: 243-254.